Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy

Younes Belkouchi, Hugues Talbot, Nathalie Lassau, Littisha Lawrance, Siham Farhane, Rahma Feki-Mkaouar, Joya Hadchiti, Lama Dawi, Julien Vibert, Paul-Henry Cournède, Clara Cousteix, Camille Mazza, Michèle Kind, Antoîne Italiano, Aurélien Marabelle, Samy Ammari, Stéphane ChampiatClinical 2023 · DOI

Abstract

The iPD score provides oncologists with a new evaluation, computable at first progression, to decide whether treatment should be continued (for the GP group), or immediately changed for the PP and CP groups. Further validation on larger cohorts is needed to prove its efficacy in clinical practice.
BibTeX
@inproceedings{belkouchi2023better,
  author = {Younes Belkouchi and Hugues Talbot and Nathalie Lassau and Littisha Lawrance and Siham Farhane and Rahma Feki-Mkaouar and Joya Hadchiti and Lama Dawi and Julien Vibert and Paul-Henry Cournède and Clara Cousteix and Camille Mazza and Michèle Kind and Antoîne Italiano and Aurélien Marabelle and Samy Ammari and Stéphane Champiat},
  title = {{Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1158/1078-0432.ccr-22-0890},
}

Loading related content...

Figure